Lonza uses its ‘global footprint’ in hematopoietic commercialization agreement
Lonza and AllCells are both manufacturers of hematopoietic stem cells, with Lonza producing them at facilities in North Carolina, while AllCell has facilities in California.
A Lonza spokesperson told us, that per this agreement, cells from both manufacturers will now be offered through Lonza’s portfolio and will bear Lonza branding “significantly expanding the range of products available to researchers.”
“By working together, we are able to bring a larger range of products to a broader worldwide customer base. Lonza’s global footprint expands access to customers around the globe, while AllCells portfolio fills some key gaps in Lonza’s existing [hemato]Poietics cell offering,” the Lonza spokesperson added.
Scientists will now be able to access this expanded portfolio of hematopoietic cells to further research in drug discovery, toxicity testing, cell therapy, and personalized medicines beyond North American borders.
In a statement, Don Klabunde, CEO, AllCells, explained, “By leveraging our customization expertise, speed and flexibility to manufacture hematopoietic cells of superior viability and quality, and with Lonza's extensive reach, we will improve the availability of highly purified cells from different tissue sources to enhance a variety of research needs.”
Hematopoietic primary cells are often used in in vitro research because the cells reflect in vivo morphology, metabolism, and growth characteristics. Researchers have expressed that obtaining these cells often requires finding multiple donors and performing a series of cell isolations.
